|MDACC Study No:||2009-0902 (clinicaltrials.gov NCT No: NCT01063907)|
|Title:||An Open-Label, Dose Escalation, Multicenter Phase I/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma|
|Principal Investigator:||Robert Orlowski|
|Treatment Agent:||Bortezomib; KW-2478|
|Study Description:||The goal of Phase I of this clinical research study is to find the highest |
tolerable doses of KW-2478 and bortezomib when given in combination to
patients with MM.
The goal of Phase II of this clinical research study is to learn if KW-2478 in
combination with bortezomib can help to control MM. The safety of this drug
combination will be studied in both phases.